SPX5551 / Spexis - LARVOL DELTA

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B cell lymphoma models (AACR 2023) - "Drugs included ibrutinib, copanlisib, idelalisib...These results were confirmed using the clinically available drug candidate balixafortide (SPX6326, POL6326).RNA-Seq in the MCL REC1 model showed a much bigger impact of the SPX5551+ibrutinib on transcriptome than single agents: 2100 transcripts differentially expressed in the combination group vs DMSO (P<0.01), 662 (ibrutinib), 260 (SPX5551)... Results suggest that a combination with the CXCR4 inhibitor SPX5551 adds beneficial effect to BCR inhibitors and might overcome resistance to PI3K/BTK inhibitors. Adding SPX551 to the treatment of patients with B cell lymphoma warrants further exploration."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BIRC3 • CCL3 • CXCL10 • CXCR3 • CXCR4 • MIR17HG • MIR92A1 • RELA

Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas (GlobeNewswire) - "Spexis AG...announced results from an in vitro study evaluating the effects of combining Spexis’ potent CXCR4 inhibitor balixafortide (BLX) with several conventional or targeted therapies on the market in B-cell lymphoma models....The study results demonstrated that the addition of either BLX or another CXCR4 inhibitor from the Spexis macrocycles platform, SPX5551, to conventional or targeted therapies, including the BCR-ABL tyrosine kinase inhibitor imatinib, the P13K inhibitor copanlisib and the BTK inhibitor ibrutinib, showed an increase in anti-proliferative activity, either additive or synergistic, across all tested B-cell lymphomas. These data suggest that the addition of balixafortide or SPX5551 has the potential to improve the effect of BCR inhibitors and may overcome resistance to BTK and PI3K inhibitors in the treatment of patients with certain types of B-cell lymphoma."

Preclinical • Hematological Malignancies • Lymphoma • Oncology